Elmiron Pigmentary Maculopathy lawsuit settlement criteria
Since our initial coverage of the Elmiron litigation, the legal landscape surrounding pentosan polysulfate sodium (PPS) has shifted dramatically. As of early 2026, the multidistrict litigation (MDL) in the District of New Jersey has resolved the vast majority of filed cases, with settlement frameworks now firmly established. For patients who took Elmiron for interstitial cystitis and later developed pigmentary maculopathy, understanding the current settlement criteria is essential before pursuing a claim.
MDL No. 2973 Settlement Tiers and the Janssen Agreement
The Elmiron MDL, formally In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation, reached a landmark global settlement agreement with Janssen Pharmaceuticals in late 2024. By 2026, the claims administrator has processed over 8,000 claims, with compensation amounts determined by a tiered system based on objective clinical findings. The settlement does not require plaintiffs to prove that Elmiron caused their maculopathy—only that they meet specific diagnostic criteria and have a documented history of taking the drug for at least two years.
| Settlement Tier | Required Clinical Findings | Minimum Cumulative Dose | Estimated Payout Range (2026) |
|---|---|---|---|
| Tier 1 (Mild) | Paracentral scotoma on visual field; no pigmentary changes on OCT | 500 g PPS (approx. 4 years of 100 mg/day) | $25,000 – $75,000 |
| Tier 2 (Moderate) | Pigmentary changes on fundus autofluorescence; visual acuity 20/40 to 20/80 | 1,000 g PPS (approx. 7 years of 100 mg/day) | $100,000 – $250,000 |
| Tier 3 (Severe) | Geographic atrophy or choroidal neovascularization; visual acuity ≤20/200 | 1,500 g PPS (approx. 10+ years of 100 mg/day) | $350,000 – $750,000 |
Importantly, the settlement applies only to claims filed before the opt-out deadline of December 2024. Patients who did not file by that date must pursue individual lawsuits, which now face stricter statute-of-limitations challenges in many states.
Diagnostic Documentation Requirements from Retina Specialists
The single most common reason for claim denial in 2025-2026 has been insufficient diagnostic evidence. The settlement agreement requires a retina specialist—not a general ophthalmologist—to confirm the diagnosis using specific testing protocols. We strongly advise patients to obtain the following records before contacting an attorney:
- Optical coherence tomography (OCT) showing characteristic hyperreflective deposits in the retinal pigment epithelium, often described as a "beaded" appearance at the level of Bruch's membrane.
- Fundus autofluorescence (FAF) demonstrating a perifoveal ring of hyperautofluorescence with a central hypoautofluorescent zone, a pattern distinct from age-related macular degeneration.
- Visual field testing (Humphrey 10-2) revealing a paracentral scotoma that correlates with the pigmentary changes.
- Multifocal electroretinography (mfERG) in ambiguous cases, showing reduced amplitude in the central 10 degrees.
- Complete medication history including pharmacy records, prescription bottles, and physician notes documenting daily dosage and duration of Elmiron use.
"The Elmiron litigation has been one of the most complex pharmaceutical mass torts in recent memory because the retinal toxicity is dose-dependent and often mimics age-related macular degeneration. Patients who took the drug for fewer than two years or at lower doses have a much harder path to settlement." — Dr. Lisa Chen, Retina Specialist, Wills Eye Hospital (testimony in MDL No. 2973, 2024).
For official MDL updates, see the New Jersey District Court MDL page. For archived case documents, refer to our original analysis on banksgermany.com.
Statute of Limitations and State-by-State Filing Windows in 2026
One of the most critical developments in 2026 is the tightening of filing deadlines across multiple jurisdictions. While the MDL settlement covered federal claims, state court actions remain subject to individual statutes of limitations. In New York, for example, plaintiffs have three years from the date of diagnosis, but in California, the window is just one year from the date the plaintiff knew or should have known that Elmiron caused their injury. Several states, including Texas and Florida, have already dismissed late-filed claims under the "discovery rule," arguing that the link between Elmiron and maculopathy was widely reported by 2020. Patients diagnosed after January 2023 generally have stronger standing, as they can credibly claim they did not discover the connection earlier.
For those still considering a lawsuit, we recommend contacting a firm specializing in pharmaceutical mass torts immediately. The settlement fund, while substantial, is finite, and late-stage claimants may face reduced payouts or exclusion from the master settlement agreement. As of our last review in February 2026, approximately $1.2 billion has been allocated to the settlement fund, with roughly 15% remaining for unresolved claims.
We will continue to monitor this litigation as new diagnostic criteria emerge and as Janssen faces parallel claims in European markets where Elmiron was marketed under different brand names.